Clincosm LogoSign in Get a demo

Infection, Human Immunodeficiency Virus

Showing 1 - 25 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK744, GSK744 LA, TMC278 LA)

Active, not recruiting
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Birmingham, Alabama
  • +49 more
Dec 26, 2022

Infection, Human Immunodeficiency Virus, HIV, Arthralgia Trial in Orel, St. Petersburg, Madrid (DTG 50 mg /ABC 600 mg /3TC 300

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • +2 more
  • DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
  • Orel, Russian Federation
  • +2 more
Sep 9, 2022

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil

Active, not recruiting
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Dolutegravir (DTG)
  • +2 more
  • Phoenix, Arizona
  • +89 more
Jun 27, 2022

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK1349572, Raltegravir, GSK1349572 Placebo)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Birmingham, Alabama
  • +180 more
Mar 14, 2022

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir)

Active, not recruiting
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Dolutegravir/abacavir/lamivudine FDC
  • +3 more
  • Phoenix, Arizona
  • +88 more
Feb 8, 2022

(APR): Multi-sponsor Registry to Detect Any Major Teratogenic

Recruiting
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Any Antiretroviral Therapy
  • Wilmington, North Carolina
    GSK Investigational Site
Oct 4, 2021

Infection, Human Immunodeficiency Virus, HIV Trial in Cambridge (GSK3640254, Placebo)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Cambridge, United Kingdom
    GSK Investigational Site
May 28, 2021

Infection, Human Immunodeficiency Virus Trial (cabotegravir, CAB)

Available
  • Infection, Human Immunodeficiency Virus
  • cabotegravir, CAB
  • (no location specified)
May 19, 2021

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (DTG 50 mg, EFV 600 mg)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • DTG 50 mg
  • EFV 600 mg
  • Ciudad de Buenos Aires, Buenos Aires, Argentina
  • +27 more
Dec 18, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Baltimore (GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • GSK2838232 100 mg tablet
  • +3 more
  • Baltimore, Maryland
    GSK Investigational Site
Oct 6, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Gent (Blood sampling)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Blood sampling
  • Gent, Belgium
    GSK Investigational Site
Sep 25, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir)

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Phoenix, Arizona
  • +73 more
Sep 28, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Cambridge (Cabotegravir, Rifabutin)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Cambridge, United Kingdom
    GSK Investigational Site
Aug 27, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Lakewood, Minneapolis (GSK1265744 30 mg)

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • GSK1265744 30 mg
  • Lakewood, Colorado
  • +1 more
Aug 27, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Baltimore, Pittsburgh (Cabotegravir tablet 30 mg once daily for 28 days.,

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Cabotegravir tablet 30 mg once daily for 28 days.
  • Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
  • Baltimore, Maryland
  • +1 more
Jun 2, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Buffalo (GSK2248761 formulation 1, GSK2248761 reference formulation,

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • GSK2248761 formulation 1
  • +3 more
  • Buffalo, New York
    GSK Investigational Site
Mar 25, 2020

Human Immunodeficiency Virus-1 Infection in HIV-1 Uninfected

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Risk reduction counseling
  • +2 more
  • Guangzhou, Guangdong, China
  • +8 more
Mar 10, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Canada, United States (GSK2838232, Cobicistat)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Birmingham, Alabama
  • +13 more
Mar 2, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Canada, United States (GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • GSK1265744 10 mg
  • +6 more
  • Birmingham, Alabama
  • +47 more
Jan 21, 2020

Infection, Human Immunodeficiency Virus, HIV Trial in Berlin (BMS-955176, Placebo matching with BMS-955176, Atazanavir)

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Berlin, Germany
    GSK Investigational Site
Nov 4, 2019

Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus Trial in Minneapolis (GSK1349572)

Completed
  • Healthy Subjects
  • +3 more
  • Minneapolis, Minnesota
    GSK Investigational Site
Jul 29, 2019

Infection, Human Immunodeficiency Virus, HIV Trial in Overland Park (DTG, RPV, DTG/RPV FDC)

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Overland Park, Kansas
    GSK Investigational Site
Jul 11, 2019

Infection, Human Immunodeficiency Virus, HIV Trial in Austin (GSK1349572)

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Austin, Texas
    GSK Investigational Site
Jun 20, 2019

Infection, Human Immunodeficiency Virus Trial in Overland Park (Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC

Completed
Has Results
  • Infection, Human Immunodeficiency Virus
  • Overland Park, Kansas
    GSK Investigational Site
Oct 10, 2018

Infection, Human Immunodeficiency Virus, HIV Trial in Fargo (YASMIN, GSK2248761, Placebo)

Terminated
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Fargo, North Dakota
    GSK Investigational Site
Feb 18, 2019